{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:12:59Z","timestamp":1792239179894,"version":"4.4.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,10,24]]},"abstract":"<jats:p>The authors report a phase 1 study of romidepsin combined with oral 5-azacytidine in patients with relapsed\/refractory lymphomas, including complete remissions in 3 patients with angioimmunoblastic T-cell lymphoma.<\/jats:p>","DOI":"10.1182\/blood.2019001285","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T19:25:18Z","timestamp":1567193118000},"page":"1395-1405","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":126,"title":["Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study"],"prefix":"10.1182","volume":"134","author":[{"given":"Owen A.","family":"O\u2019Connor","sequence":"first","affiliation":[{"name":"Center for Lymphoid Malignancies, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1531-3838","authenticated-orcid":false,"given":"Lorenzo","family":"Falchi","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Lue","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Marchi","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Kinahan","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Sawas","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changchun","family":"Deng","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Montanari","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Amengual","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye A.","family":"Kim","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishling M.","family":"Rada","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Khan","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice T.","family":"Jacob","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Malanga","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Francescone","sequence":"additional","affiliation":[{"name":"Department of Radiology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Nandakumar","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cell Biology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig R.","family":"Soderquist","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cell Biology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cell Biology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6250-048X","authenticated-orcid":false,"given":"Govind","family":"Bhagat","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cell Biology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Statistics, Mailman School of Public Health, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Risue\u00f1o","sequence":"additional","affiliation":[{"name":"Celgene Institute for Translational Research Europe, Seville, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7953-7625","authenticated-orcid":false,"given":"Daniel","family":"Menezes","sequence":"additional","affiliation":[{"name":"Translational Development, Celgene Corporation, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei R.","family":"Shustov","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington School of Medicine, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomir","family":"Sokol","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center, University of South Florida, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Scotto","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,8,30]]},"reference":[{"issue":"1","key":"2019111601524972200_B1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronn\u00e9","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111601524972200_B2","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111601524972200_B3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"issue":"12","key":"2019111601524972200_B4","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1038\/bcj.2014.83","article-title":"Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice","volume":"4","author":"Muto","year":"2014","journal-title":"Blood Cancer J"},{"issue":"2","key":"2019111601524972200_B5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"issue":"4","key":"2019111601524972200_B6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng.2916","article-title":"A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma","volume":"46","author":"Yoo","year":"2014","journal-title":"Nat Genet"},{"issue":"2","key":"2019111601524972200_B7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"issue":"9","key":"2019111601524972200_B8","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood-2017-11-818617","article-title":"RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice","volume":"132","author":"Ng","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2019111601524972200_B9","doi-asserted-by":"crossref","first-page":"P259","DOI":"10.1016\/j.ccell.2018.01.001","article-title":"RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis","volume":"33","author":"Cortes","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"2019111601524972200_B10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.13566","article-title":"The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma","volume":"171","author":"Marchi","year":"2015","journal-title":"Br J Haematol"},{"key":"2019111601524972200_B11","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/hon.2439_180","article-title":"Azacytidine and decitabine exhibit differential effects on cytotoxicity and methylation and exhibit class synergy with HDACI in models of PTCL","volume":"35","author":"Scotto","year":"2017","journal-title":"Hematol Oncol"},{"issue":"5","key":"2019111601524972200_B12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111601524972200_B13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"key":"2019111601524972200_B14","first-page":"34","article-title":"Bioanalytical method validation","year":"2013"},{"key":"2019111601524972200_B15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejca.2018.11.028","article-title":"Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer","volume":"108","author":"Levy","year":"2019","journal-title":"Eur J Cancer"},{"issue":"25","key":"2019111601524972200_B16","doi-asserted-by":"crossref","first-page":"37636","DOI":"10.18632\/oncotarget.9400","article-title":"Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders","volume":"7","author":"Margolskee","year":"2016","journal-title":"Oncotarget"},{"issue":"32","key":"2019111601524972200_B17","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111601524972200_B18","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-08-1215","article-title":"Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma","volume":"15","author":"Woo","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2019111601524972200_B19","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111601524972200_B20","doi-asserted-by":"crossref","first-page":"e0135520","DOI":"10.1371\/journal.pone.0135520","article-title":"Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies","volume":"10","author":"Laille","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"2019111601524972200_B21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/0091270004271947","article-title":"Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes","volume":"45","author":"Marcucci","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"18","key":"2019111601524972200_B22","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111601524972200_B23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4164.4164","article-title":"Treatment with hypomethylating agent 5-azacytidine induces sustained response in angioimmunoblastic T cell lymphomas [abstract]","volume":"128","author":"Delarue","year":"2016","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/17\/1395\/1502423\/bloodbld2019001285.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/17\/1395\/1502423\/bloodbld2019001285.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T01:52:59Z","timestamp":1573869179000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/17\/1395\/374967\/Oral-5azacytidine-and-romidepsin-exhibit-marked"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":23,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2019,8,30]]},"published-print":{"date-parts":[[2019,10,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019001285","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736524765.793577580","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,30]]}}}